Ampa Inc.

Ampa Inc. , based in the US, specializes in brain-stimulation technologies designed to enhance mental health treatment, offering innovative solutions that target resilience and emotional strength through advanced Transcranial Magnetic Stimulation techniques. Founded in 2022 in Palo Alto, US, Ampa Inc. develops brain-stimulation solutions to improve mental health outcomes.

The company completed its first funding round in October 2025, raising USD 8. 5 mn in a Seed round led by Nexus NeuroTech Ventures with participation from Satori Capital, Morningside, Continuum Health Ventures, and Zabara Foundation. Ampa has no known subsidiaries or parent companies and does not appear to have undergone significant pivots in its business strategy since inception. Ampa specializes in advanced Transcranial Magnetic Stimulation (TMS) technology, specifically through its flagship product, the Ampa One system.

This innovative platform is designed to enhance brain circuits related to resilience and inner strength, aiming to alleviate symptoms associated with depression and other mental health disorders. The Ampa One system is characterized by its user-friendly, lightweight design, making it suitable for clinical applications. Clinicians utilize this technology to provide effective, non-invasive treatment options for patients, contributing to higher remission rates compared to traditional TMS solutions. Ampa's services are primarily targeted at healthcare providers and mental health professionals across various geographical markets, including the United States, where the demand for accessible mental health care solutions continues to grow.

The company serves a diverse client base that includes hospitals, private practices, and outpatient clinics, focusing on improving patient outcomes in mental health treatment. Ampa’s revenue model is primarily based on the sale of its TMS technology, with the Ampa One system being a key income generator. The company engages in direct sales to healthcare providers, enabling them to incorporate TMS therapy into their treatment offerings. Transactions typically involve one-time purchases of the Ampa One system along with ongoing service agreements that may include maintenance and support.

Ampa also facilitates partnerships with insurers to cover TMS therapy, ensuring that patients can access the treatment without prohibitive out-of-pocket costs. The company's pricing structure reflects the high value of its technology and services, catering to both B2B transactions with healthcare facilities and direct consumer engagement through partnerships. By addressing a crucial need in the mental health sector, Ampa positions itself to expand its influence on patient care and outcomes. In October 2025, Ampa Inc.

raised USD 8. 5 mn in a Seed round, which will be used to expand the distribution of its portable brain-stimulation device and support the implementation of its one-day treatment program nationwide. The company aims to launch additional products that will enhance its offerings in mental health treatment, while strategically targeting growth in various markets across the United States. This funding is pivotal in facilitating Ampa's expansion plans and enhancing its service delivery.